WebThe Next Leap in Dyslipidemia Management. Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet … Staten was founded by Prof. Alan Tall, Prof. Daniel Rader, and Dr. Paul da Silva … Board of Directors . Executive Team . Advisory Board Our lead antibody STT-5058 has recycling properties that are pH-dependent and … December 17, 2024. Staten Biotechnology B.V. and Novo Nordisk A/S announce … Staten Biotechnology B.V. Transistorweg 5J. 6534 AT Nijmegen. The Netherlands … She has for the last 15 years served as member of board of directors in a … Alan Tall, Co-founder and Advisor. Alan Tall is the Tilden-Weger-Bieler Professor of … Prior to joining Staten Biotech, Hilde served as Head of Strategic Innovation … WebDec 17, 2024 · Staten Biotechnology develops novel and innovative strategies for the treatment of dyslipidemia, with a focus on hypertriglyceridemia treatment. With a unique approach towards neutralizing ApoC3, a key molecule in dyslipidaemia management, Staten Biotechnology is developing STT-5058, a humanized, monoclonal antibody, licensed from …
Staten Biotechnology Strikes $488 Million Deal With Novo
WebDec 17, 2024 · Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will... WebMar 6, 2024 · Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, with a focus on the triglyceride space. Staten Biotechnology B.V. was incorporated in 2014 by world experts in dyslipidemia, Paul da Silva Jardine, Daniel Rader and Alan Tall. Daniela Couto is the Managing Director. d and d heavy wooden shield
Staten Biotechnology - Overview, News & Competitors - ZoomInfo
WebDec 17, 2024 · Staten Biotechnology develops novel and innovative strategies for the treatment of dyslipidemia, with a focus on hypertriglyceridaemia treatment. With a unique approach towards neutralizing ApoC3, a key molecule in dyslipidaemia management, Staten Biotechnology is developing STT-5058, a humanized, monoclonal antibody, licensed from … WebDec 18, 2024 · Staten Biotechnology and Novo Nordisk have announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics … WebJul 21, 2024 · Staten Biotechnology B.V. aims to develop novel and innovative strategies for the treatment of dyslipidaemia, with a focus on hypertriglyceridemia treatment. … d and d hero forge